ClinicalTrials.gov record
Terminated Phase 3 Interventional

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

ClinicalTrials.gov ID: NCT02258854

Public ClinicalTrials.gov record NCT02258854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US)

Study identification

NCT ID
NCT02258854
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
XOMA (US) LLC
Industry
Enrollment
69 participants

Conditions and interventions

Conditions

Interventions

  • Dose 2 gevokizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2014
Primary completion
Sep 30, 2017
Completion
Nov 30, 2017
Last update posted
Oct 15, 2015

2014 – 2017

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
33
Facility City State ZIP Site status
Not listed Chandler Arizona
Not listed Phoenix Arizona
Not listed Beverly Hills California
Not listed Redlands California
Not listed Riverside California
Not listed Sacramento California
Not listed Santa Ana California
Not listed Victorville California
Not listed Golden Colorado
Not listed Littleton Colorado
Not listed Bridgeport Connecticut
Not listed Lakeland Florida
Not listed Tampa Florida
Not listed Chicago Illinois
Not listed Indianapolis Indiana
Not listed Ellsworth Maine
Not listed Baltimore Maryland
Not listed Cambridge Massachusetts
Not listed Waltham Massachusetts
Not listed Jackson Michigan
Not listed Royal Oak Michigan
Not listed Omaha Nebraska
Not listed Bloomfield New Jersey
Not listed Teaneck New Jersey
Not listed Belmont North Carolina
Not listed Charlotte North Carolina
Not listed Winston-Salem North Carolina
Not listed Fargo North Dakota
Not listed Dallas Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Salt Lake City Utah
Not listed Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02258854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2015 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02258854 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →